US2013071443A1PendingUtilityA1
Glycosaminoglycans
Est. expirySep 16, 2031(~5.1 yrs left)· nominal 20-yr term from priority
C08B 37/0078A61P 9/10A61L 2300/412A61K 31/737A61L 27/54A61L 27/34A61K 31/727A61K 38/1866
58
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
Heparan sulphate HS7 is disclosed, together with the use of HS7 in the growth and/or development and/or regeneration of tissue.
Claims
exact text as granted — not AI-modifiedWe claim:
1 . Isolated or substantially purified heparan sulphate HS7, wherein following digestion with heparin lyases I, II and III and then subjecting the resulting disaccharide fragments to capillary electrophoresis analysis the heparan sulphate HS7 has a disaccharide composition comprising:
Disaccharide
Normalised weight percentage
ΔUA,2S-GlcNS,6S
11.08 ± 3.0
ΔUA,2S-GlcNS
4.46 ± 2.0
ΔUA-GlcNS,6S
15.84 ± 3.0
ΔUA,2S-GlcNAc,6S
4.76 ± 2.0
ΔUA-GlcNS
20.27 ± 3.0
ΔUA,2S-GlcNAc
1.01 ± 0.5
ΔUA-GlcNAc,6S
10.63 ± 3.0
ΔUA-GlcNAc
31.95 ± 3.0
2 . Isolated or substantially purified heparan sulphate HS7 wherein following digestion with heparin lyases I, II and III and then subjecting the resulting disaccharide fragments to capillary electrophoresis analysis the heparan sulphate HS7 has a disaccharide composition comprising:
Disaccharide
Normalised weight percentage
ΔUA,2S-GlcNS,6S
11.08 ± 1.0
ΔUA,2S-GlcNS
4.46 ± 0.4
ΔUA-GlcNS,6S
15.84 ± 1.0
ΔUA,2S-GlcNAc,6S
4.76 ± 0.6
ΔUA-GlcNS
20.27 ± 3.0
ΔUA,2S-GlcNAc
1.01 ± 0.4
ΔUA-GlcNAc,6S
10.63 ± 1.0
ΔUA-GlcNAc
31.95 ± 1.6
3 . HS7 according to claim 1 wherein the HS7 is capable of binding SEQ ID NO:1 or 2.
4 . HS7 according to claim 1 obtained by a method comprising:
(i) providing a solid support having polypeptide molecules adhered to the support, wherein the polypeptide comprises a heparin-binding domain having the amino acid sequence of SEQ ID NO:1;
(ii) contacting the polypeptide molecules with a mixture comprising glycosaminoglycans such that polypeptide-glycosaminoglycan complexes are allowed to form;
(iii) partitioning polypeptide-glycosaminoglycan complexes from the remainder of the mixture;
(iv) dissociating glycosaminoglycans from the polypeptide-glycosaminoglycan complexes; and
(v) collecting the dissociated glycosaminoglycans.
5 . HS7 according to claim 4 wherein the mixture comprising glycosaminoglycans is a heparan sulphate preparation obtained from porcine mucosa.
6 . A composition, pharmaceutical composition or medicament comprising HS7 according to claim 1 .
7 . The composition, pharmaceutical composition or medicament of claim 6 wherein the composition, pharmaceutical composition or medicament further comprises VEGF protein.
8 . A method of treating a disease, condition or injury to tissue in a patient, the method comprising administration of a therapeutically effective amount of HS7 according to claim 1 to the patient, thereby treating a disease, condition or injury to tissue of the patient.
9 . The method of claim 8 wherein the method involves the stimulation or promotion of the growth of blood vessels in the patient.
10 . The method of claim 8 wherein the method comprises administering HS7 to tissue at or surrounding a wound or location on the patient's body at which blood vessel growth is required.
11 . The method of claim 8 wherein the method further comprises administering VEGF protein to the patient.
12 . A method of treating a disease, condition or injury to tissue in a patient, the method comprising surgically implanting a biocompatible implant or prosthesis, which implant or prosthesis comprises a biomaterial and HS7 according to claim 1 , into tissue of the patient at or surrounding the site of the disease, condition or injury.
13 . A biocompatible implant or prosthesis comprising a biomaterial and isolated or substantially purified HS7 according to claim 1 .
14 . The implant or prosthesis of claim 13 wherein the implant or prosthesis is coated with said HS7.
15 . The implant or prosthesis of claim 13 wherein the implant or prosthesis is impregnated with said HS7.
16 . A method of forming a biocompatible implant or prosthesis, the method comprising the step of coating or impregnating a biomaterial with isolated or substantially purified HS7 according to claim 1 .
17 . A method of promoting growth of blood vessels, the method comprising administering isolated or substantially purified HS7 according to claim 1 to vascular cells or to vascular tissue.
18 . The method of claim 17 wherein the vascular cells or vascular tissue are contacted with HS7 in vitro.
19 . The method of claim 17 wherein the vascular cells or vascular tissue are contacted with HS7 in vivo.Join the waitlist — get patent alerts
Track US2013071443A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.